---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066969"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:18:16.357039+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC

## Summary
- Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).
- Cash and equivalents $1.01B at March 31, 2025, down from $1.03B at Dec 31, 2024.
- R&D expenses $25.1M (Q1 2025) vs $14.1M (Q1 2024); net loss $23.5M vs $14.8M.
- Additional JANX007 and JANX008 data expected in H2 2025; R&D Day planned mid-2025.
- Selected two dose regimens (0.3/2/6mg and 0.3/2/9mg) for Phase 1b expansion.

## SEC filing metadata
- accession: 0000950170-25-066969
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017025066969/0000950170-25-066969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017025066969/janx-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066969
- JSON: https://secwatch.observer/filing/0000950170-25-066969.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.